Russian watchdog investigating cartel in Russian pharma market

26 August 2016

The Russian Federal Anti-Monopoly Service (FAS) has started investigations regarding the recent detection of a cartel in the Russian pharmaceutical market, which was created by some leading local drugmakers and global majors operating in the Russian market, according to press-service of the FAS, reports The Pharma Letter’s local correspondent.

According to results of the preliminary investigation that were recently announced by the FAS, members of the cartel had reached an informal agreement to maintain prices for drugs supplied to Russian hospitals on the pre-set limit.

In addition, the involved companies were able to coordinate prices during the conduct of state tenders and auctions for the supply of drugs for state needs.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK